Please login to the form below

Not currently logged in
Email:
Password:

spondyloarthritis

This page shows the latest spondyloarthritis news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis. Novartis has unveiled more positive phase 3 data for Cosentyx, this time in patients with non-radiographic axial spondyloarthritis (nr-axSpA). .

Latest news

  • Novartis eyes potential new indication for Cosentyx Novartis eyes potential new indication for Cosentyx

    The new data comes from the Swiss pharma’s PREVENT trial, in patients with non-radiographic axial spondyloarthritis (nr-axSpA). ... earlier in axial spondyloarthritis,” said John Tsai (pictured below), head of global drug development and chief

  • UCB supports social network for SpA patients UCB supports social network for SpA patients

    MySpondylitisTeam is launched by MyHealthTeams. UCB has partnered with MyHealthTeams to launch a new social network called MySpondylitisTeam for patients with the chronic and inflammatory arthritis spondyloarthritis (SpA). ... Eric Peacock, co-founder

  • Lilly pilots enhanced online trial information Lilly pilots enhanced online trial information

    The pilot project has so far been added to two clinical trials, a study of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis and one of Cialis (tadalafil) in pediatric patients with

  • NOR-SWITCH - the final piece in the biosimilar puzzle? NOR-SWITCH - the final piece in the biosimilar puzzle?

    The patient populations for each indication were: 155 Crohn's disease, 93 ulcerative colitis, 78 rheumatoid arthritis, 91 spondyloarthritis, 30 psoriatic arthritis and 35 plaque psoriasis.

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    Already approved for psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), Novartis has a pivotal trial in non-radiographic axial spondyloarthritis on-going as well as head-to-head superiority trials

More from news
Approximately 4 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    Category: Supporting Patients and Professionals. DUET: Harnessing the Power of Collaboration from Concept to Completion – Improving Patient Care in Spondyloarthritis,  by AbbVie,  with support from Lucid Group.

  • Infographic: Spondyloarthritis

    Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,

  • Research Partnership

    Infographic: Spondyloarthritis. ... Overview of spondyloarthritis patient profiles and treatment pathways.

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics